OncoC4 Announces Cesalatamig Abstract Presentation at SITC
Data from a global Phase 1/2 study in PD-(L)1-resistant or refractory NSCLC are scheduled for presentation November 7.
Data from a global Phase 1/2 study in PD-(L)1-resistant or refractory NSCLC are scheduled for presentation November 7.